ACHL Stock Summary and Trading Ideas (Achilles Therapeutics PLC - American Depositary Shares | NASDAQ:ACHL)

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ACHL.

As of April 19, 2024, ACHL stock price declined to $0.78 with 187,822 million shares trading.

ACHL has a beta of 1.09, meaning it tends to be more sensitive to market movements. ACHL has a correlation of 0.04 to the broad based SPY ETF.

ACHL has a market cap of $31.92 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACHL stock traded as high as $17.06 and as low as $.74.

ACHL has underperformed the market in the last year with a price return of -12.7% while the SPY ETF gained +21.2%. ACHL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.3% and -13.3%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

ACHL support price is $.76 and resistance is $.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHL stock will trade within this expected range on the day.